NYSE:BSXMedical Equipment
How Strong Q1 Results and FARAPULSE Data At Boston Scientific (BSX) Have Changed Its Investment Story
In the first quarter of 2026, Boston Scientific reported sales of US$5,203 million and net income of US$1,341 million, with basic and diluted EPS from continuing operations of US$0.90, and issued guidance for reported net sales growth of 5.5%–7.5% for Q2 and 7.0%–8.5% for 2026.
Shortly after the earnings release, new clinical data from the AVANT GUARD trial and other studies further supported the safety and effectiveness of the FARAPULSE pulsed field ablation platform and WATCHMAN left...